Bluejay Diagnostics (BJDX) Net Cash Flow Growth (1y) (2021 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -53.07% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 17.60% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | -562.50% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | -283.58% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | -564.44% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 76.43% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | -31.84% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -394.13% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 57.36% |
| 10 | Bluejay Diagnostics | 572,394.44 | -3.11 Mn | - | -24.84% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -24.84% |
| Dec 31, 2025 | 255.20% |
| Sep 30, 2025 | 40.90% |
| Jun 30, 2025 | -75.41% |
| Mar 31, 2025 | -361.98% |
| Dec 31, 2024 | 49.32% |
| Sep 30, 2024 | -9,711.14% |
| Jun 30, 2024 | 420.98% |
| Mar 31, 2024 | 113.58% |
| Dec 31, 2023 | 9.87% |
| Sep 30, 2023 | 98.86% |
| Jun 30, 2023 | 5.66% |
| Mar 31, 2023 | -73.27% |
| Dec 31, 2022 | -119.04% |
| Sep 30, 2022 | -2,818.84% |
| Jun 30, 2022 | -182.77% |
| Mar 31, 2022 | -189.97% |
| Dec 31, 2021 | 1,891.16% |